copper-64/67 based theranostic pair targeting alpha-V/beta-3 (Clarity Pharmaceuticals/Memorial Sloan Kettering Cancer Center)

N/A

Report date: 2025/10/28 16:06:59

Base Information

Drug Namecopper-64/67 based theranostic pair targeting alpha-V/beta-3 (Clarity Pharmaceuticals/Memorial Sloan Kettering Cancer Center)
Drug Alias Namecopper-64-SAR-bisRGD + copper-67-SAR-bisRGDSAR-bisRGD-[64Cu] + SAR-bisRGD-[67Cu][64Cu]-SAR-bisRGD + [67Cu]-SAR-bisRGD
ClassificationBiologics > Protein drugs > Recombinant polypeptideDiagnostic agent (In vivo)Radiation-emitting products > Radioactive diagnostic agent +[7] 
Mechanisms of ActionPositron-emission tomography enhancersIntegrin alpha-V/beta-3 modulators
TargetsIntegrin alpha-V/beta-3
Therapy Area/IndicationsCarcinoma, Pancreatic Ductal
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustralia and New Zealand
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMemorial Sloan Kettering Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesMemorial Sloan Kettering Cancer CenterClarity Pharmaceuticals Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Pancreatic Ductal
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A